First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
European Journal of Cancer · 2024-12 · 213 · 115070
DOI: 10.1016/j.ejca.2024.115070 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024-12. Verfasst von Oleksandr Dudnichenko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Kharkiv Regional Oncology Center, Kharkiv, Ukraine. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Combined Chemotherapy Protocols, Sulfonamides, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kharkiv Regional Oncology Center, Kharkiv, Ukraine.
- Private Medical Institution Euromedservice, St. Petersburg, Russia.
- Sarah Cannon Research Institute, Nashville, TN, USA.
- Unit of Medical Oncology, University of Perugia, Perugia, Italy.
- Department of Skin and Soft Tissue Tumors, National Cancer Institute, Kiev, Ukraine.
- Department of Medicine, Division of Hematology & Oncology, University of Tennessee Medical Center, Knoxville, TN, USA.
Förderung
- Pfizer
Zitieren
APA
Dudnichenko, O., Penkov, K., McKean, M., Mandalà, M., Kukushkina, M., Panella, T., Csőszi, T., Gerletti, P., Thakur, M., Polli, A., di Pietro, A., & Schadendorf, D. (2024). First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study. European Journal of Cancer, 213, 115070. https://doi.org/10.1016/j.ejca.2024.115070
Vancouver
Dudnichenko O, Penkov K, McKean M, Mandalà M, Kukushkina M, Panella T, et al. First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study. European Journal of Cancer. 2024;213:115070. doi:10.1016/j.ejca.2024.115070
BibTeX
@article{Dudnichenko2024,
author = {Dudnichenko, Oleksandr and Penkov, Konstantin and McKean, Meredith and Mandalà, Mario and Kukushkina, Mariia and Panella, Timothy and Csőszi, Tibor and Gerletti, Paola and Thakur, Mahgull and Polli, Anna and di Pietro, Alessandra and Schadendorf, Dirk},
title = {First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study},
journal = {European Journal of Cancer},
year = {2024},
volume = {213},
pages = {115070},
doi = {10.1016/j.ejca.2024.115070}
}
EUVIMED